Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Lymphoma | Research article

Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies

Authors: Ting Zhang, Jing Sun, Jinying Li, Yunuo Zhao, Tao Zhang, Ruoning Yang, Xuelei Ma

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

CC chemokine receptor 4 (CCR4), the receptor for CCL22 and CCL17, is expressed on the surface of effector Tregs that have the highest suppressive effects on antitumor immune response. CCR4 is also widely expressed on the surface of tumor cells from patients with adult T-cell leukemia/lymphoma (ATL), peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). Mogamulizumab is a humanized, IgG1 kappa monoclonal antibody that is directed against CCR4. By reducing the number of CCR4-positive Tregs and tumor cells, the mogamulizumab can reduce tumor burden and boost antitumor immunity to achieve antitumor effects.

Methods

We examined the PubMed and ClinicalTrials.gov until 1 February 2020. Considering variability in different studies, we selected the adverse events (AEs), overall survival (OS), progression-free survival (PFS), objective responses rate (ORR) and Hazard Ratio (HR) for PFS to evaluate the safety and efficacy profile of mogamulizumab.

Results

When patients were treated with mogamulizumab monotherapy, the most common all-grade AEs were lymphopenia, infusion reaction, fever, rash and chills while the most common grade ≥ 3 AEs were lymphopenia, neutropenia and rash. When patients were treated with combined therapy of mogamulizumab and other drugs, the most common all-grade AEs were neutropenia, anaemia, lymphopenia and gastrointestinal disorder, while the most common grade ≥ 3 AEs was lymphopenia. For patients treated with mogamulizumab monotherapy, the pooled ORR and mean PFS were 0.430 (95% CI: 0.393–0.469) and 1.060 months (95% CI: 1.043–1.077), respectively. For patients treated with combined therapy of mogamulizumab and other drugs, the pooled ORR was 0.203 (95% CI: 0.022–0.746) while the pooled PFS and OS were 2.093 months (95% CI: 1.602–2.584) and 6.591 months (95% CI: 6.014–7.167), respectively.

Conclusions

Based on present evidence, we believed that mogamulizumab had clinically meaningful antitumor activity with acceptable toxicity which is a novel therapy in treating patients with cancers.

Yoshie O, Matsushima KJII. CCR4 and its ligands: from bench to bedside. Int immun. 2015;27(1):11–20.

Wu XS, Lonsdorf AS, STJJoID H. Cutaneous T-Cell Lymphoma: Roles for Chemokines and Chemokine Receptors. J Invest Dermatol 2009;129(5):1115–9.

Sokolowska-Wojdylo M, Wenzel J, Gaffal E, Lenz J, TTJBJo D. Circulating clonal CLA+ and CD4+ T cells in Sézary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. Br J Dermatol 2005;152(2):258–64.

Susumu, Suzuki, Takashi, Ishida, Kazuhiro, Yoshikawa, Ryuzo, Oncology UJJJoC: Current status of immunotherapy. 2016.

Ferenczi K, Fuhlbrigge RC, Pinkus J, Pinkus GS, Kupper TS. Increased CCR4 expression in cutaneous T cell lymphoma. J invest Dermatol 2002;119(6):1405–10.

Sugaya M, Morimura S, Suga H, Kawaguchi M, Miyagaki T, Ohmatsu H, et al. CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis. J Dermatol 2015;42(6):613–5.

Duvic M. Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome. Hematol Am Soc Hematol Educ Program. 2015;2015(1):529–44. https://doi.org/10.1182/asheducation-2015.1.529.CrossRef

Duvic M, Evans M, Wang C. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016;7(3):171–4. https://doi.org/10.1177/2040620716636541.CrossRefPubMedPubMedCentral

Ishida. Research TJCC: CXC Chemokine Receptor 3 and CC Chemokine Receptor 4 Expression in T-Cell and NK-Cell Lymphomas with Special Reference to Clinicopathological Significance for Peripheral T-Cell Lymphoma, Unspecified. Clin Cancer Res. 2004;10(16):5494–500.

10.

Mukai M, Mould D, Maeda H, Narushima K, Greene D. Exposure-response analysis for Mogamulizumab in adults with cutaneous T-cell lymphoma. J Clin Pharmacol. 2020;60(1):50–7. https://doi.org/10.1002/jcph.1548.CrossRefPubMed

11.

Sekine M, Kubuki Y, Kameda T, Takeuchi M, Toyama T, Kawano N, et al. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice. Eur J Haematol. 2017;98(5):501–7. https://doi.org/10.1111/ejh.12863.CrossRefPubMed

12.

Kasamon YL, Chen H, de Claro RA, Nie L, Ye J, Blumenthal GM, et al. FDA approval summary: Mogamulizumab-kpkc for mycosis Fungoides and Sézary syndrome. Clin Cancer Res. 2019;25(24):7275–80. https://doi.org/10.1158/1078-0432.CCR-19-2030.CrossRefPubMed

13.

Wan X, Wang W, Liu J, TJBmrm T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014;14:135.

14.

Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125(12):1883–9. https://doi.org/10.1182/blood-2014-09-600924.CrossRefPubMedPubMedCentral

15.

Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837–42. https://doi.org/10.1200/JCO.2011.37.3472.CrossRefPubMed

16.

Ishitsuka K, Yurimoto S, Kawamura K, Tsuji Y, Iwabuchi M, Takahashi T, et al. Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance. Int J Hematol. 2017;106(4):522–32. https://doi.org/10.1007/s12185-017-2270-9.CrossRefPubMed

17.

Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–204. https://doi.org/10.1016/S1470-2045(18)30379-6.CrossRefPubMed

18.

Kurose K, Ohue Y, Wada H, Iida S, Ishida T, Kojima T, et al. Phase Ia study of FoxP3+ CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in Cancer patients. Clin Cancer Res. 2015;21(19):4327–36. https://doi.org/10.1158/1078-0432.CCR-15-0357.CrossRefPubMed

19.

Nakashima J, Imaizumi Y, Taniguchi H, Ando K, Iwanaga M, Itonaga H, et al. Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma. Int J Hematol. 2018;108(5):516–23. https://doi.org/10.1007/s12185-018-2509-0.CrossRefPubMed

20.

Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):1157–63. https://doi.org/10.1200/JCO.2013.52.0924.CrossRefPubMed

21.

Phillips AA, Fields PA, Hermine O, Ramos JC, Beltran BE, Pereira J, et al. Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica. 2019;104(5):993–1003. https://doi.org/10.3324/haematol.2018.205096.CrossRefPubMedPubMedCentral

22.

Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28(9):1591–8. https://doi.org/10.1200/JCO.2009.25.3575.CrossRefPubMed

23.

Zinzani PL, Karlin L, Radford J, Caballero D, Fields P, Chamuleau MED, et al. European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma. Haematologica. 2016;101(10):e407–10. https://doi.org/10.3324/haematol.2016.146977.CrossRefPubMedPubMedCentral

24.

Cohen EEW, Pishvaian MJ, Shepard DR, Wang D, Weiss J, Johnson ML, et al. A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. J Immunother Cancer. 2019;7(1):342. https://doi.org/10.1186/s40425-019-0815-6.CrossRefPubMedPubMedCentral

25.

Doi T, Muro K, Ishii H, Kato T, Tsushima T, Takenoyama M, et al. A phase I study of the anti-CC chemokine receptor 4 antibody, Mogamulizumab, in combination with Nivolumab in patients with advanced or metastatic solid tumors. Clin Cancer Res. 2019;25(22):6614–22. https://doi.org/10.1158/1078-0432.CCR-19-1090.CrossRefPubMed

26.

Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169(5):672–82. https://doi.org/10.1111/bjh.13338.CrossRefPubMedPubMedCentral

27.

Study of mogamulizumab + docetaxel in subjects with non-small cell lung cancer. Available from: http:// clinicaltrialsgov/show/NCT02358473.

28.

Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 2005;11(6):2327.

29.

Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res. 2010;16(5):1520–31. https://doi.org/10.1158/1078-0432.CCR-09-2697.CrossRefPubMed

30.

Ni X, Langridge T, Duvic MJO. Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab. Oncoimmunology 2015;4(7):e1011524.

31.

Remer M, Al-Shamkhani A, Glennie M, Johnson PJI. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas. Immuno 2014;6(11):1187–206.

32.

Campbell JJ. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature. 1999;400(6746):776–80.

33.

Girardi M, Heald PW, LDJNEJoM W. The Pathogenesis of Mycosis Fungoides. New Eng J Med. 2004;350(19):1978–88.

34.

Kinnunen T, Chamberlain N, Morbach H, Choi J, Kim S, Craft J, et al. Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood; 2013;121(9):1595–603.

35.

Suzuki Y, Saito M, Ishii T, Urakawa I, Matsumoto A, Masaki A, et al. Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma. Clin Cancer Res 2019;25(14):4388–99.

36.

Saito M, Ishii T, Urakawa I, Matsumoto A, Ishida TJBA. Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma. Blood adv; 2020;4(10):2180–91.

37.

Ishida T, Ito A, Sato F, Kusumoto S, Iida S, Inagaki H, et al. Ueda RJCe: Stevens–Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci; 2013;104(5):647–50.

38.

Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, et al. Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome. Cancer Res. 2009;69(5):2000–9.

39.

Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003;278(5):3466–73.

40.

Ishida T. Science RUJC: CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 2006;97(11):1139–46.

41.

Segal NH, He AR, Doi T, Levy R, Bhatia S, Pishvaian MJ, et al. Huang BJCCR: Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. Clin Cancer Res 2018;1078–0432:CCR-1017-1922.

Title: Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies
Authors: Ting Zhang
Jing Sun
Jinying Li
Yunuo Zhao
Tao Zhang
Ruoning Yang
Xuelei Ma
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Lymphoma
Solid Tumor
Lymphopenia
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08363-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model

Characteristics of gastric precancerous conditions and Helicobacter pylori infection among dyspeptic patients in north-eastern Iran: is endoscopic biopsy and histopathological assessment necessary?

Prognostic value of ubiquitin E2 UBE2W and its correlation with tumor-infiltrating immune cells in breast cancer

Relationship between chronic exposure to ambient air pollution and mental health in Korean adult cancer survivors and the general population

Preferences of first-degree relatives of gastric cancer patients for gastric cancer screening: a discrete choice experiment

Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer